References of "DETRY, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailResults of kidney transplantation from controlled donors after cardio-circulatory death: a single center experience.
Ledinh, H.; WEEKERS, Laurent ULg; BONVOISIN, Catherine ULg et al

in Transplant International (2012), 25

The aim of this study was to determine results of kidney transplantation (KT) from controlled donation after cardio-circulatory death (DCD). Primary end-points were graft and patient survival, and post ... [more ▼]

The aim of this study was to determine results of kidney transplantation (KT) from controlled donation after cardio-circulatory death (DCD). Primary end-points were graft and patient survival, and post-transplant complications. The influence of delayed graft function (DGF) on graft survival and DGF risk factors were analyzed as secondary end-points. This is a retrospective mono-center review of a consecutive series of 59 DCD-KT performed between 2005 and 2010. Overall graft survival was 96.6%, 94.6%, and 90.7% at 3 months, 1 and 3 years, respectively. Main cause of graft loss was patient's death with a functioning graft. No primary nonfunction grafts. Renal graft function was suboptimal at hospital discharge, but nearly normalized at 3 months. DGF was observed in 45.6% of all DCD-KT. DGF significantly increased postoperative length of hospitalization, but had no deleterious impact on graft function or survival. Donor body mass index >/=30 was the only donor factor that was found to significantly increase the risk of DGF (P < 0.05). Despite a higher rate of DGF, controlled DCD-KT offers a valuable contribution to the pool of deceased donor kidney grafts, with comparable mid-term results to those procured after brain death. [less ▲]

Detailed reference viewed: 63 (28 ULg)
Full Text
Peer Reviewed
See detailOutcome of the living kidney donor
DELANAYE, Pierre ULg; WEEKERS, Laurent ULg; DUBOIS, Bernard ULg et al

in Nephrology Dialysis Transplantation (2012), 27(1), 41-50

Renal transplantation from living kidney donors is still relatively marginal in most of the European countries. However, this source of kidney grafts may help to overcome in part the organ donor shortage ... [more ▼]

Renal transplantation from living kidney donors is still relatively marginal in most of the European countries. However, this source of kidney grafts may help to overcome in part the organ donor shortage of cadaveric donors. The living donor strategy implies correct and objective information about donation risks and completely free acceptance of the living candidate of the donation. In this paper, we reviewed the consequences of kidney donation on the living donor health, considering very short term (linked to the surgery), short term (effect of nephrectomy on glomerular filtration rate) and long term (risk of mortality, chronic kidney disease, proteinuria and hypertension) consequences of kidney donation. [less ▲]

Detailed reference viewed: 38 (8 ULg)
Full Text
Peer Reviewed
See detailSurgical management of acute cholecystitis: results of a 2-year prospective multicenter survey in Belgium.
Navez, Benoit; Ungureanu, Felicia; Michiels, Martens et al

in Surgical Endoscopy (2012), 26(9), 2436-2445

BACKGROUND: Laparoscopic cholecystectomy is considered nowadays as the standard management of acute cholecystitis (AC). However, results from multicentric studies in the general surgical community are ... [more ▼]

BACKGROUND: Laparoscopic cholecystectomy is considered nowadays as the standard management of acute cholecystitis (AC). However, results from multicentric studies in the general surgical community are still lacking. METHODS: A prospective multicenter survey of surgical management of AC patients was conducted over a 2-year period in Belgium. Operative features and patients' clinical outcome were recorded. The impact of independent predictive factors on the choice of surgical approach, the risk of conversion, and the occurrence of postoperative complications was studied by multivariate logistic regression analysis. RESULTS: Fifty-three surgeons consecutively and anonymously included 1,089 patients in this prospective study. A primary open approach was chosen in 74 patients (6.8%), whereas a laparoscopic approach was the first option in 1,015 patients (93.2%). Independent predictive factors for a primary open approach were previous history of upper abdominal surgery [odds ratio (OR) 4.13, p < 0.001], patient age greater than 70 years (OR 2.41, p < 0.05), surgeon with more than 10 years' experience (OR 2.08, p = 0.005), and gangrenous cholecystitis (OR 1.71, p < 0.05). In the laparoscopy group, 116 patients (11.4%) required conversion to laparotomy. Overall, 38 patients (3.5%) presented biliary complications and 49 had other local complications (4.5%). Incidence of bile duct injury was 1.2% in the whole series, 2.7% in the open group, and 1.1% in the laparoscopy group. Sixty patients had general complications (5.5%). The overall mortality rate was 0.8%. All patients who died were in poor general condition [American Society of Anesthesiologists (ASA) III or IV]. CONCLUSIONS: Although laparoscopic cholecystectomy is currently considered as the standard treatment for acute cholecystitis, an open approach is still a valid option in more advanced disease. However, overall mortality and incidence of bile duct injury remain high. [less ▲]

Detailed reference viewed: 28 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
Winston, D. J.; Saliba, F.; Blumberg, E. et al

in American Journal of Transplantation (2012), 12(11), 3021-30

Maribavir is an oral benzimidazole riboside with potent in vitro activity against cytomegalovirus (CMV), including some CMV strains resistant to ganciclovir. In a randomized, double-blind, multicenter ... [more ▼]

Maribavir is an oral benzimidazole riboside with potent in vitro activity against cytomegalovirus (CMV), including some CMV strains resistant to ganciclovir. In a randomized, double-blind, multicenter trial, the efficacy and safety of prophylactic oral maribavir (100 mg twice daily) for prevention of CMV disease were compared with oral ganciclovir (1000 mg three times daily) in 303 CMV-seronegative liver transplant recipients with CMV-seropositive donors (147 maribavir; 156 ganciclovir). Patients received study drug for up to 14 weeks and were monitored for CMV infection by blood surveillance tests and also for the development of CMV disease. The primary endpoint was Endpoint Committee (EC)-confirmed CMV disease within 6 months of transplantation. In a modified intent-to-treat analysis, the noninferiority of maribavir compared to oral ganciclovir for prevention of CMV disease was not established (12% with maribavir vs. 8% with ganciclovir: event rate difference of 0.041; 95% CI: -0.038, 0.119). Furthermore, significantly fewer ganciclovir patients had EC-confirmed CMV disease or CMV infection by pp65 antigenemia or CMV DNA PCR compared to maribavir patients at both 100 days (20% vs. 60%; p < 0.0001) and at 6 months (53% vs. 72%; p = 0.0053) after transplantation. Graft rejection, patient survival, and non-CMV infections were similar for maribavir and ganciclovir patients. Maribavir was well-tolerated and associated with fewer hematological adverse events than oral ganciclovir. At a dose of 100 mg twice daily, maribavir is safe but not adequate for prevention of CMV disease in liver transplant recipients at high risk for CMV disease. [less ▲]

Detailed reference viewed: 40 (0 ULg)
Full Text
Peer Reviewed
See detailDelayed graft function does not harm the future of donation-after-cardiac death in kidney transplantation.
Le Dinh, Hieu; WEEKERS, Laurent ULg; BONVOISIN, Catherine ULg et al

in Transplantation Proceedings (2012), 44(9), 2795-802

INTRODUCTION: Delayed graft function (DGF) occurs more frequently in kidney transplants from donation after cardiac death (DCD) than from donation after brain death (DBD). We investigated the effect of ... [more ▼]

INTRODUCTION: Delayed graft function (DGF) occurs more frequently in kidney transplants from donation after cardiac death (DCD) than from donation after brain death (DBD). We investigated the effect of DGF on posttransplantation outcomes among grafts from controlled DCD kidneys. PATIENTS AND METHODS: This single-center retrospective study recruited 80 controlled DCD kidneys transplanted from January 2005 to December 2011. Mean patient follow-up was 28.5 months. RESULTS: There were no primary nonfunction grafts; the DGF rate was 35.5%. Overall graft survival rates between groups with versus without DGF were 92.4% and 95.2% at 1 year, 92.4% and 87.1% at 3 years, and 84.7% and 87.1% at 5 years, respectively (P = not significant (NS)). Patients with versus without DGF showed the same survival rates at the corresponding time 92.4% vs 97.2%, 92.4% vs 93.9%, and 84.7% vs 93.9% (P = NS). Estimated glomerular filtration rate was significantly lower in the DGF compared with the non-DGF group at hospital discharge (29 vs 42 mL/min; P = .00) and at 6 months posttransplantation (46 vs 52 mL/min; P = .04), but the difference disappeared thereafter: 47 vs 52 mL/min at 1 year, 50 vs 48 mL/min at 3 years, and 54 vs 53 mL/min at 5 years (P = NS). DGF did not increase the risk of an acute rejection episode (29.6% vs 30.6%; P = NS) or rate of surgical complications (33.3% vs 26.5%; P = NS). However, DGF prolonged significantly the length of hospitalization in the DGF versus the non- DGF group (18.9 vs 13 days; P = .00). Donor body mass index (BMI) >/= 30 kg/m(2), recipient BMI >/=30 kg/m(2), and pretransplantation dialysis duration increased the risk of DGF upon multivariate logistic regression analysis. CONCLUSIONS: Apart from the longer hospital stay, DGF had no deleterious impact on the future of kidney allografts from controlled DCD, which showed comparable graft and patient survivals, renal function, rejection rates, and surgical complications as a group without DGF. Therefore, DGF should no longer be considered to be a medical barrier to the use of kidney grafts from controlled DCD. [less ▲]

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailChoice of key-words for a scientific paper.
VAN DAMME, Hendrik ULg; DETRY, Olivier ULg; Lerut, J et al

in Acta Chirurgica Belgica (2012), 112(2), 107

Detailed reference viewed: 28 (2 ULg)
Full Text
Peer Reviewed
See detailPlease Doctor, Resist NOTES!
DETRY, Olivier ULg

in Annals of Surgery (2011), 254(5), 839-840

Detailed reference viewed: 24 (7 ULg)
Full Text
Peer Reviewed
See detailPRESERVATION OF NORMAL MORPHOLOGY OF HUMAN LIVERS AFTER 24 HOURS OF HYPOTHERMIC MACHINE PERFUSION. A FIRST-IN-MAN STUDY
Monbaliu, D.; Liu, Q.; Libbrecht, L. et al

in Transplant International (2011, September), 24(2), 151-151

Detailed reference viewed: 32 (7 ULg)
Full Text
Peer Reviewed
See detailLIVER TRANSPLANTATION FROM DONATION AFTER CARDIOCIRCULATORY DEATH (DCD) DONORS: BELGIAN EXPERIENCE 2003-2009
DE ROOVER, Arnaud ULg; Le Dinh, Hieu ULg; Cicarelli, Olga et al

in Transplant International (2011, September), 24(2), 84-84

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailBELGIAN EXPERIENCE OF DCD KIDNEY TRANSPLANTATION
Darius, Tom; Jochmans, Ina; Ledinh, Hieu et al

in Transplant International (2011, September), 24(2), 43-44

Detailed reference viewed: 56 (3 ULg)
Full Text
Peer Reviewed
See detailMULTICENTER BELGIAN SURVEY ON DONOR MORBIDITY AND MORTALITY IN ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION
Troisi, Roberto I; Vogelaers, Dirk; Lerut, Jan et al

in Transplant International (2011, September), 24(2), 13-13

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients.
Noterdaeme, Timothee; Longree, Luc; Bataille, Christian ULg et al

in World journal of gastroenterology : WJG (2011), 17(25), 3069-72

Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute ... [more ▼]

Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good. [less ▲]

Detailed reference viewed: 39 (2 ULg)
Full Text
Peer Reviewed
See detailDCD liver transplantation: is donor age an issue?
DETRY, Olivier ULg; Le dinh, Hieu; DE ROOVER, Arnaud ULg et al

in Liver Transplantation (2011, July), 17(6S1), 112

Detailed reference viewed: 31 (4 ULg)
Full Text
See detailDéfaillance neurologique au cours de l'insuffisance hépatique aigüe
DETRY, Olivier ULg

Conference (2011, June 16)

Detailed reference viewed: 22 (0 ULg)
Full Text
See detailRFA, résection et/ou transplantation: Sélection des malades et pronostic
DETRY, Olivier ULg

Conference (2011, May 24)

Detailed reference viewed: 12 (1 ULg)
Full Text
See detail"Classical Lichtenstein procedure" under local anasthetics
DETRY, Olivier ULg

Conference (2011, May 12)

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailLaparoscopic repair of colonoscopic perforation: a new standard?
Coimbra Marques, Carla ULg; Bouffioux, Laurent ULg; Kohnen, Laurent ULg et al

in Surgical Endoscopy (2011), 25

BACKGROUND: Scientific evidence demonstrating interest in the laparoscopic approach for surgical repair of colonoscopic perforations is still lacking. The authors retrospectively reviewed the records of ... [more ▼]

BACKGROUND: Scientific evidence demonstrating interest in the laparoscopic approach for surgical repair of colonoscopic perforations is still lacking. The authors retrospectively reviewed the records of 43 patients who suffered from colonic perforations after colonoscopy between 1989 and 2008 in two tertiary centers in order to compare the results of the laparoscopic and the open approaches to repair. METHODS: The patients' demographic data, perforation location, therapy, and outcome were recorded from the medical charts. Forty-two patients were managed operatively (19 laparoscopies and 23 laparotomies). In three patients who underwent explorative laparoscopy, the procedure had to be converted to laparotomy due to surgical difficulties. The patients who underwent laparotomy management had a longer period between the colonoscopy and the surgery (P = 0.056) and more stercoral contaminations. RESULTS: The mean hospital stay was shorter for the laparoscopy group (P = 0.02), which had fewer postoperative complications (P = 0.01) and no mortality (NS). CONCLUSION: This series demonstrates that early laparoscopic management of colonoscopic perforation is safe. Laparoscopic management may lead to reduced surgical and psychological stress for the patient because of its low morbidity and mortality rates and shorter hospital stay. However, the procedure should be converted to a laparotomy if necessary. [less ▲]

Detailed reference viewed: 108 (9 ULg)
Full Text
See detailLiver transplantation for donation after cardiocirculatory death donors: Belgian experience 2003-2009
DE ROOVER, Arnaud ULg; Ledinh, H.; Donckier, V. et al

Conference (2011, March 24)

Detailed reference viewed: 14 (2 ULg)
Full Text
See detailDCD liver transplantation: is donor age an issue?
DETRY, Olivier ULg; le dinh, Hieu; Honoré, Pierre ULg et al

Conference (2011, March 24)

Detailed reference viewed: 16 (1 ULg)